These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10955356)

  • 21. [Raynaud's disease, acrocyanosis and scleroderma in the menopause].
    Lo Stumbo F; Banchelli A
    Minerva Ginecol; 1965 Nov; 17(21):1034-43. PubMed ID: 5880755
    [No Abstract]   [Full Text] [Related]  

  • 22. Peculiarities in dermatology. A case of the Thiebierge-Weissen-bach type of systemic scleroderma associated with circumscribed calcinosis and Raynaud's disease.
    Kingsley HJ
    Cent Afr J Med; 1968 Mar; 14(3):59-60. PubMed ID: 5649072
    [No Abstract]   [Full Text] [Related]  

  • 23. Low plasma protein nitrotyrosine levels distinguish primary Raynaud's phenomenon from scleroderma.
    Kingdon EJ; Mani AR; Frost MT; Denton CP; Powis SH; Black CM; Moore KP
    Ann Rheum Dis; 2006 Jul; 65(7):952-4. PubMed ID: 16308344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis.
    Dowd PM; Kovacs IB; Bland CJ; Kirby JD
    Br Med J (Clin Res Ed); 1981 Aug; 283(6287):350. PubMed ID: 6788326
    [No Abstract]   [Full Text] [Related]  

  • 25. Raynaud's syndrome; acrosclerosis; scleroderma.
    JABLONSKA S; BUBNOW B; LUKASIAK B
    Br J Dermatol; 1958 Feb; 70(2):37-43. PubMed ID: 13510539
    [No Abstract]   [Full Text] [Related]  

  • 26. Elevated serum homocysteine levels in paediatric patients with primary Raynaud's phenomenon.
    Kutilek S; Nemec V; Bockayova E
    Rev Bras Reumatol; 2012; 52(1):128-30. PubMed ID: 22286653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon?
    Ingegnoli F; Gualtierotti R; Schioppo T; Orenti A; Boracchi P; Lubatti C; Mastaglio C; Galbiati V; Murgo A; Zeni S; Grossi C; Borghi O; Rosenberg W; Castelnovo L; Meroni Pier L
    Ann Rheum Dis; 2014 May; 73(5):940-1. PubMed ID: 24344159
    [No Abstract]   [Full Text] [Related]  

  • 28. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis.
    Sulli A; Soldano S; Pizzorni C; Montagna P; Secchi ME; Villaggio B; Seriolo B; Brizzolara R; Cutolo M
    J Rheumatol; 2009 Jun; 36(6):1235-9. PubMed ID: 19369451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome.
    Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD; Mikhailidis DP; Jeremy JY; Dandona P
    Prostaglandins Leukot Med; 1985 Jun; 18(3):401-2. PubMed ID: 3895252
    [No Abstract]   [Full Text] [Related]  

  • 30. Association between homocysteinemia and renal function in patients with type 2 diabetes mellitus.
    Ozmen B; Ozmen D; Turgan N; Habif S; Mutaf I; Bayindir O
    Ann Clin Lab Sci; 2002; 32(3):279-86. PubMed ID: 12175091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidant/antioxidant status in patients with Raynaud's disease.
    Biondi R; Coaccioli S; Lattanzi S; Puxeddu A; Papini M
    Clin Ter; 2008; 159(2):77-81. PubMed ID: 18463765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spontaneous neutrophil activation in patients with primary Raynaud's phenomenon and systemic sclerosis.
    Stevens TR; Hall ND; McHugh NJ; Maddison PJ
    Br J Rheumatol; 1992 Dec; 31(12):856. PubMed ID: 1458295
    [No Abstract]   [Full Text] [Related]  

  • 33. [Raynaud's syndrome and scleroderma. I. Scleroderma-like changes in Raynaud's syndrome and their differentiation from scleroderma].
    JABLONSKA S; LUKASIAK B; BUBNOW B
    Pol Tyg Lek (Wars); 1957 Sep; 12(39):1481-6. PubMed ID: 13505250
    [No Abstract]   [Full Text] [Related]  

  • 34. Generalized scleroderma with Raynaud's phenomena. Report of a case.
    Elmostehy MR; Bissada NF
    Egypt Dent J; 1970 Jan; 16(1):83-8. PubMed ID: 5268450
    [No Abstract]   [Full Text] [Related]  

  • 35. [The usefulness of plasma cystatin C determination as a marker of glomerular filtration rate].
    Symonides B; Wieteska M; Bobilewicz D
    Przegl Lek; 2007; 64(1):54-8. PubMed ID: 18183833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. S-cystatin C formulae or combination of s-cystatin C and s-creatinine formulae do not improve prediction of GFR.
    Urbaniak J; Weyde W; Smolska D; Zagocka E; Klak R; Kusztal M; Krajewska M; Wozniak M; Klinger M
    Nephrol Dial Transplant; 2008 Jul; 23(7):2425-6; author reply 2426-7. PubMed ID: 18388120
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of haemostatic parameters and circadian variations of the haemostatic system in patients with systemic sclerosis and Raynaud's phenomenon.
    Trifiletti A; Bartolone S; Scamardi R; Pizzoleo MA; Sottilotta G; Larosa D; Barbera N
    Panminerva Med; 2000 Mar; 42(1):7-9. PubMed ID: 11019597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [One stage parathyroidectomy and stellectomy for Raynaud's disease associated with scleroderma].
    ARMENIO S; VEGNI L
    Atti Accad Fisiocrit Siena Med Fis; 1955; 2():444-51. PubMed ID: 13341699
    [No Abstract]   [Full Text] [Related]  

  • 39. Plasma cystatin C for estimating residual GFR (rGFR) in dialysis patients.
    Tidman M; Sjöström P; Jones I
    Nephrol Dial Transplant; 2008 Mar; 23(3):1072-3; author reply 1073. PubMed ID: 17984103
    [No Abstract]   [Full Text] [Related]  

  • 40. Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis.
    Mok MY; Cheung BM; Lo Y; Leung RY; Wong WS; Lau CS
    J Rheumatol; 2007 Nov; 34(11):2224-9. PubMed ID: 17937467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.